DEF 14A: BioSig Technologies Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Amendment

BioSig Technologies is asking shareholders to vote on a reverse stock split and an amendment to their long-term incentive plan at the upcoming annual meeting.

Summary

• BioSig Technologies has scheduled its 2024 Annual Meeting of Stockholders for December 31, 2024, to be held virtually.
• The company is seeking approval for several proposals, including the election of five directors, a reverse stock split, an amendment to the long-term incentive plan, and ratification of the appointment of Marcum LLP as their independent auditor.
• The proposed reverse stock split would allow the Board to combine outstanding shares at a ratio between 1-for-2 and 1-for-10, aiming to increase the stock price to meet Nasdaq listing requirements.
• The company also proposes to increase the number of shares available under the 2023 Long-Term Incentive Plan by 3,500,000, bringing the total to 4,376,595 shares.
• The board recommends voting for all proposals, including the election of Anthony Amato, Frederick D. Hrkac, Christopher A. Baer, Donald F. Browne, and Steven E. Abelman as directors.

Sentiment

Score: 6

Explanation: The document is neutral in tone, focusing on procedural matters and required approvals. While there are some positive aspects, such as the potential for increased stock price, there are also risks and challenges, such as the potential for delisting and a lawsuit. The sentiment is therefore moderately positive.

Positives

• The proposed reverse stock split aims to increase the stock price, potentially helping the company maintain its Nasdaq listing.
• Increasing the shares available under the long-term incentive plan could help attract and retain key personnel.
• The board is recommending a vote for all proposals, indicating confidence in the proposed actions.
• The company is using the SEC's Notice and Access model to reduce costs and environmental impact.

Negatives

• The reverse stock split could potentially decrease the liquidity of the stock.
• There is a risk that the reverse stock split may not increase the stock price over the long term.
• The company does not currently have a diverse director as required by Nasdaq listing rules.
• A lawsuit has been filed against the company by a former employee seeking at least $288,000 in damages.

Risks

• The reverse stock split may not increase the stock price and could lead to a decrease in overall market capitalization.
• The company may be delisted from The Nasdaq Capital Market if it does not meet the minimum bid price requirements.
• The company is involved in a legal proceeding with a former employee, which could result in financial losses.
• The company does not currently have a diverse director as required by Nasdaq listing rules.

Future Outlook

The company aims to increase its stock price to maintain its Nasdaq listing and to provide incentives to employees, consultants, and directors through the long-term incentive plan.

Management Comments

• On behalf of the Board of Directors, I urge you to submit your vote as soon as possible, even if you currently plan to attend the online-only meeting.
• Thank you for your support of our company. I look forward to seeing you at the Annual Meeting.

Industry Context

The proposed reverse stock split is a common strategy for companies facing delisting from major exchanges due to low stock prices. The amendment to the long-term incentive plan is also a standard practice to attract and retain talent in the competitive biotech industry.

Comparison to Industry Standards

• Reverse stock splits are frequently used by companies listed on exchanges like Nasdaq to maintain compliance with minimum share price requirements, similar to actions taken by other small-cap biotech firms facing similar challenges.
• The proposed increase in shares for the long-term incentive plan is within the range of what is seen in the biotech industry, where equity compensation is a key tool for attracting and retaining talent, comparable to companies like XOMA Corporation and Agenus Inc.
• The company's board composition, while lacking diversity as per Nasdaq guidelines, is similar to other small-cap companies that may face challenges in attracting diverse candidates with specific industry expertise, such as those seen in the boards of companies like Veru Inc. and Cassava Sciences Inc.

Legal Proceedings

• A lawsuit has been filed against the company by a former employee seeking at least $288,000 in damages. The company believes the allegations are baseless and intends to contest them vigorously.

Related Party Transactions

• On March 22, 2022, James Klein, before joining the board, purchased 11,000 shares and warrants at $14.00 per share.
• On November 14, 2022, Mr. Klein exercised his 11,000 warrants for 11,000 shares at $2.50 per share.
• On February 8, 2023, former CFO Mr. Buhaly participated in a private placement, acquiring 23,289 shares and 11,645 warrants for $200,000.
• On November 2, 2023, Mr. Hrkac, then an independent board member, was appointed Executive Vice President and entered into a consulting agreement at $12,500 per month.
• On December 28, 2023, Mr. Hrkac was granted 90,000 restricted stock units and options to purchase 60,000 shares.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, which could affect the value and liquidity of their shares.
• Employees may benefit from the increased shares available under the long-term incentive plan.
• The company's ability to maintain its Nasdaq listing could impact investor confidence and the company's overall valuation.
• The outcome of the lawsuit could have financial implications for the company and its stakeholders.

Next Steps

• Stockholders are urged to vote on the proposals before the December 31, 2024 meeting.
• The Board will determine the exact ratio of the reverse stock split if approved by stockholders.
• The company will file the reverse stock split amendment with the Secretary of State of Delaware if approved by stockholders and the Board.
• The company will continue to defend against the lawsuit filed by a former employee.

Key Dates

Keywords

reverse stock split, annual meeting, proxy statement, long-term incentive plan, director election, Nasdaq listing, Marcum LLP, stockholder vote, corporate governance, executive compensation